Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Precision oncology startup 4baseCare has raised Rs 128 crore. This funding will expand its genomics labs globally and scale its AI platform...

Zahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...

Pharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...

The recent trade accord between India and Oman represents a significant leap toward energy independence and economic integration. Experts n...

Wockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected t...

Indian equities face a mixed outlook due to potential monsoon deficit and uneven corporate earnings. While rural-linked sectors may see pre...

The company said its diagnostics business crossed an annualised revenue run rate of more than Rs 600 crore during the year, growing over 40...

Market expert Daljeet Kohli advises investors to focus on quality stocks at discounted prices, rather than the Nifty's movement. He highlig...

Indian equity investors, frustrated by stagnant returns, are urged by Sandeep Neema of PL Asset Management to distinguish weak sentiment fr...

Metropolis Healthcare is set for its next growth phase. The diagnostic chain will focus on genomics and specialty diagnostics. Strategic ac...

Prices for generic semaglutide, a popular weight-loss drug, are expected to fall by more than half in the coming months. This sharp decline...

Geopolitical tensions, particularly the Iran crisis, are overshadowing strong corporate earnings, according to Dipan Mehta. While India Inc...

Cohance Lifesciences shares dropped significantly after reporting an 84% year-on-year decline in March-quarter net profit. Jefferies downgr...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

Market expert Dipan Mehta finds India's current earnings season strong. He notes that future quarters will test corporate India due to pote...

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.